Carcinogenesis Advance Access originally published online on July 4, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Carcinogenesis, Vol. 24, No. 10, 1671-1676,
October 2003
© 2003 Oxford University Press
MOLECULAR EPIDEMIOLOGY AND CANCER PREVENTION |
Association of the DNA repair gene XPD Asp312Asn polymorphism with p53 gene mutations in tobacco-related non-small cell lung cancer
1 Department of Environmental and Occupational Health, 2 Department of Medicine, 3 Department of Biostatistics, 4 Department of Pharmacology, 5 Department of Surgery, 6 Department of Pathology and 7 The University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA 15260, USA and 8 The Veterans Administration Health Care System, Pittsburgh, PA 15240, USA
Lung cancer, a disease related mostly to tobacco smoke exposure and a leading cause of cancer-related death in industrialized countries, is frequently associated with mutations in the p53 tumor suppressor gene. Genetic differences resulting in inter-individual variation in DNA repair capacity may in part account for susceptibility of a cell to genotoxic agents leading to somatic mutations, including p53 mutations, and eventual transformation of a normal cell into a malignant phenotype. The objective of this study is to investigate the relationship between the polymorphisms of two DNA repair genes, the nucleotide excision repair xeroderma pigmentosum group D (XPD) gene (codons 312 and 751) and the base excision repair X-ray repair cross-complementing group 1 (XRCC1) gene (codon 399), and p53 mutations among lung cancer patients. Lung tumors from 204 smokers with non-small cell lung cancer (NSCLC) were analyzed for mutations in exons 5–8 of the p53 gene and genotypes of XPD and XRCC1. p53 mutations were found in 20% (40/204) of the patients. Patients with the XPD codon 312 Asn allele were less likely to have p53 mutations (13.8%) than XPD 312 Asp/Asp (27.3%) [odds ratio (OR) 0.43, 95% confidence interval (CI) 0.20–0.89, P = 0.023]. No association was found between p53 mutations and either XPD Lys751Gln or XRCC1 Arg399Gln. However, the p53 mutation frequency increased with the increased number of the combined genotypes among XPD 312WT (Asp/Asp), XPD 751VT (Lys/Gln or Gln/Gln) or XRCC1 399VT (Arg/Gln or Gln/Gln) (P = 0.01, trend test). These results suggest that individuals who smoke and have the XPD codon 312 Asp/Asp genotype may be at a greater risk of p53 mutations, especially if combined with other polymorphisms that may result in deficient DNA repair.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. J. Alberg, J. G. Ford, and J. M. Samet Epidemiology of Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 29S - 55S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Manuguerra, F. Saletta, M. R. Karagas, M. Berwick, F. Veglia, P. Vineis, and G. Matullo XRCC3 and XPD/ERCC2 Single Nucleotide Polymorphisms and the Risk of Cancer: A HuGE Review Am. J. Epidemiol., August 15, 2006; 164(4): 297 - 302. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Mehta, T. A. Alonzo, R. B. Gerbing, J. S. Elliott, T. A. Wilke, R. J. Kennedy, J. A. Ross, J. P. Perentesis, B. J. Lange, and S. M. Davies XPD Lys751Gln polymorphism in the etiology and outcome of childhood acute myeloid leukemia: a Children's Oncology Group report Blood, January 1, 2006; 107(1): 39 - 45. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. G. Casson, Z. Zheng, S. C. Evans, P. J. Veugelers, G. A. Porter, and D. L. Guernsey Polymorphisms in DNA repair genes in the molecular pathogenesis of esophageal (Barrett) adenocarcinoma Carcinogenesis, September 1, 2005; 26(9): 1536 - 1541. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Hu, H. Ma, F. Chen, Q. Wei, and H. Shen XRCC1 Polymorphisms and Cancer Risk: A Meta-analysis of 38 Case-Control Studies Cancer Epidemiol. Biomarkers Prev., July 1, 2005; 14(7): 1810 - 1818. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Alberg, M. V. Brock, and J. M. Samet Epidemiology of Lung Cancer: Looking to the Future J. Clin. Oncol., May 10, 2005; 23(14): 3175 - 3185. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. E. Mechanic, A. J. Marrogi, J. A. Welsh, E. D. Bowman, M. A. Khan, L. Enewold, Y.-L. Zheng, S. Chanock, P. G. Shields, and C. C. Harris Polymorphisms in XPD and TP53 and mutation in human lung cancer Carcinogenesis, March 1, 2005; 26(3): 597 - 604. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-M. Gao, M. Romkes, J. M. Siegfried, J. D. Luketich, and P. Keohavong No Association between the XPD 312, 751, or XRCC1 399 Polymorphisms and K-ras Gene Mutation in Smoking Non-Small-Cell Lung Cancer Cancer Epidemiol. Biomarkers Prev., April 1, 2004; 13(4): 673 - 675. [Full Text] [PDF]
|
|